GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Oxford Immunotec Global PLC (NAS:OXFD) » Definitions » ROC (Joel Greenblatt) %

Oxford Immunotec Global (Oxford Immunotec Global) ROC (Joel Greenblatt) % : 3.58% (As of Sep. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Oxford Immunotec Global ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Oxford Immunotec Global's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was 3.58%.

The historical rank and industry rank for Oxford Immunotec Global's ROC (Joel Greenblatt) % or its related term are showing as below:

OXFD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -502.79   Med: -236.89   Max: -25
Current: -60.72

During the past 9 years, Oxford Immunotec Global's highest ROC (Joel Greenblatt) % was -25.00%. The lowest was -502.79%. And the median was -236.89%.

OXFD's ROC (Joel Greenblatt) % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -13.95 vs OXFD: -60.72

Oxford Immunotec Global's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 33.00% per year.


Oxford Immunotec Global ROC (Joel Greenblatt) % Historical Data

The historical data trend for Oxford Immunotec Global's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Immunotec Global ROC (Joel Greenblatt) % Chart

Oxford Immunotec Global Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -262.60 -233.53 -252.54 -183.78 -24.87

Oxford Immunotec Global Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.87 -25.38 -84.47 -137.08 3.58

Competitive Comparison of Oxford Immunotec Global's ROC (Joel Greenblatt) %

For the Diagnostics & Research subindustry, Oxford Immunotec Global's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford Immunotec Global's ROC (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford Immunotec Global's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Oxford Immunotec Global's ROC (Joel Greenblatt) % falls into.



Oxford Immunotec Global ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.677 + 12.824 + 3.775) - (6.499 + 0.034 + 3.248)
=11.495

Working Capital(Q: Sep. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.866 + 13.099 + 3.602) - (6.525 + 0.027 + 3.762)
=17.253

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Oxford Immunotec Global for the quarter that ended in Sep. 2020 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2020  Q: Sep. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.1/( ( (15.199 + max(11.495, 0)) + (17.493 + max(17.253, 0)) )/ 2 )
=1.1/( ( 26.694 + 34.746 )/ 2 )
=1.1/30.72
=3.58 %

Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford Immunotec Global  (NAS:OXFD) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Oxford Immunotec Global ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Oxford Immunotec Global's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Immunotec Global (Oxford Immunotec Global) Business Description

Traded in Other Exchanges
N/A
Address
143 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4SE
Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.
Executives
Andrew Scott Walton director 430 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark R. Klausner director C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Patricia Randall director C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Richard A Sandberg director 330 NEVEDA STREET, NEWTON MA 02460-1458
Patrick J Balthrop director C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Herm Rosenman director OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Peter Wrighton-smith director, officer: Chief Executive Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Mclaughlin Matthew T E officer: Chief Financial Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Stefan C Linn officer: Chief Operating Officer C/O OXFORD IMMUNOTEC GLOBAL 940 INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ
Janet Louise Kidd officer: General Counsel C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Elizabeth M Keiley officer: SVP & General Counsel C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Richard M. Altieri officer: Chief Financial Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Richard Wenstrup officer: Chief Medical Officer C/O OXFORD IMMUNOTEC GLOBAL, 94C INNOVATION DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RZ

Oxford Immunotec Global (Oxford Immunotec Global) Headlines

From GuruFocus